Deletions in human chromosome arms 11p and 13q in primary hepatocellular carcinomas - PubMed (original) (raw)
Deletions in human chromosome arms 11p and 13q in primary hepatocellular carcinomas
H P Wang et al. Cytogenet Cell Genet. 1988.
Abstract
Normal liver and hepatocellular carcinoma (HCC) genotypes were compared at loci on most of the human chromosomes with probes that detect restriction fragment length polymorphisms. Six of fourteen tumors exhibited loss of heterozygosity of one or more markers on 11p. Ten patients were informative for loci on 13q, and 5 of these 10 exhibited loss of heterozygosity for one or more of the 13q markers. Altogether, 9 of the 14 patients showed loss of a polymorphic allele for one or more loci on either 11p or 13q. A survey of loci on 16 additional chromosomes indicated that the deletions were not due to a general loss of heterozygosity in HCCs. Quantitative densitometry showed that each of the 10 deletions resulted in hemizygosity (no reduplication) of the remaining allele in tumor tissue. In contrast to hereditary embryonal tumors, in which reduplication of the remaining chromosome is the rule, simple deletion appears to be the primary mechanism responsible for the loss of heterozygosity in these adult, nonhereditary HCCs. These data show that HCCs arising in hepatitis B virus carriers are a genetically heterogeneous group of tumors, some of which may arise through 13q alterations, some through 11p alterations, some with both chromosomes altered, and some with both intact.
Similar articles
- No evidence for loss of alleles at 11p in HBV negative hepatocellular carcinomas.
Kiechle-Schwarz M, Scherer G, Kovacs G. Kiechle-Schwarz M, et al. Genes Chromosomes Cancer. 1990 Mar;1(4):312-4. doi: 10.1002/gcc.2870010409. Genes Chromosomes Cancer. 1990. PMID: 1980606 - Loss of somatic heterozygosity in hepatocellular carcinoma.
Walker GJ, Hayward NK, Falvey S, Cooksley WG. Walker GJ, et al. Cancer Res. 1991 Aug 15;51(16):4367-70. Cancer Res. 1991. PMID: 1678314 - Frequent loss of heterozygosity on chromosomes 16 and 4 in human hepatocellular carcinoma.
Zhang WD, Hirohashi S, Tsuda H, Shimosato Y, Yokota J, Terada M, Sugimura T. Zhang WD, et al. Jpn J Cancer Res. 1990 Feb;81(2):108-11. doi: 10.1111/j.1349-7006.1990.tb02534.x. Jpn J Cancer Res. 1990. PMID: 1970554 Free PMC article. - Accumulation of allelic loss on arms of chromosomes 13q, 16q and 17p in the advanced stages of human hepatocellular carcinoma.
Nishida N, Fukuda Y, Kokuryu H, Sadamoto T, Isowa G, Honda K, Yamaoka Y, Ikenaga M, Imura H, Ishizaki K. Nishida N, et al. Int J Cancer. 1992 Jul 30;51(6):862-8. doi: 10.1002/ijc.2910510605. Int J Cancer. 1992. PMID: 1322376 - [Loss of heterozygosity in hepatocellular carcinoma].
Takahashi K, Kudo J, Ishibashi H, Niho Y. Takahashi K, et al. Nihon Rinsho. 1993 Feb;51(2):370-4. Nihon Rinsho. 1993. PMID: 8096550 Review. Japanese.
Cited by
- A liver-specific lncRNA, FAM99B, suppresses hepatocellular carcinoma progression through inhibition of cell proliferation, migration, and invasion.
Mo M, Liu S, Ma X, Tan C, Wei L, Sheng Y, Song Y, Zeng X, Huang D, Qiu X. Mo M, et al. J Cancer Res Clin Oncol. 2019 Aug;145(8):2027-2038. doi: 10.1007/s00432-019-02954-8. Epub 2019 Jun 26. J Cancer Res Clin Oncol. 2019. PMID: 31243545 - PCDH9 acts as a tumor suppressor inducing tumor cell arrest at G0/G1 phase and is frequently methylated in hepatocellular carcinoma.
Lv J, Zhu P, Zhang X, Zhang L, Chen X, Lu F, Yu Z, Liu S. Lv J, et al. Mol Med Rep. 2017 Oct;16(4):4475-4482. doi: 10.3892/mmr.2017.7193. Epub 2017 Aug 8. Mol Med Rep. 2017. PMID: 28791409 Free PMC article. - The LATS1 and LATS2 tumor suppressors: beyond the Hippo pathway.
Furth N, Aylon Y. Furth N, et al. Cell Death Differ. 2017 Sep;24(9):1488-1501. doi: 10.1038/cdd.2017.99. Epub 2017 Jun 23. Cell Death Differ. 2017. PMID: 28644436 Free PMC article. Review. - Contributions of integrin-linked kinase to breast cancer metastasis and tumourigenesis.
Hinton CV, Avraham S, Avraham HK. Hinton CV, et al. J Cell Mol Med. 2008 Sep-Oct;12(5A):1517-26. doi: 10.1111/j.1582-4934.2008.00300.x. Epub 2008 Mar 19. J Cell Mol Med. 2008. PMID: 18363848 Free PMC article. Review. - Low LATS2 mRNA level can predict favorable response to epirubicin plus cyclophosphamide, but not to docetaxel, in breast cancers.
Takahashi Y, Miyoshi Y, Morimoto K, Taguchi T, Tamaki Y, Noguchi S. Takahashi Y, et al. J Cancer Res Clin Oncol. 2007 Aug;133(8):501-9. doi: 10.1007/s00432-007-0194-0. Epub 2007 Feb 13. J Cancer Res Clin Oncol. 2007. PMID: 17297610
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical